Previous 10 | Next 10 |
home / stock / nnbxf / nnbxf news
PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities ...
2023-04-29 18:15:06 ET Nanobiotix S.A. (NBTX) Q4 2022 Results Conference Call April 25, 2023 08:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Miller - Ev...
Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as planned Final data from Study 102 in head and neck cancer expected in H2 2023 ...
Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology com...
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023 PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...
PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com As a reminder, Nanobiotix has announced on December 21, 2022, that i...
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 08:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...